Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

Autor: Andrew Hsu, Kelsey E. Huntington, Andre De Souza, Lanlan Zhou, Adam J. Olszewski, Nirav P. Makwana, Diana O. Treaba, Ludimila Cavalcante, Francis J. Giles, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro

Publikováno v: Cancer Biology & Therapy, Vol 23, Iss 1, Pp 417-423 (2022)

GSK-3β is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3β blockade downregulates the NF-κB pathway, modulates immune cell PD-1 and tumor cell PD-L1 expression, and increases CD8 + T cell and NK cell functi

Externí odkaz: https://doaj.org/article/92cb5ee1490243b8bd245afdd67c0799

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

Autor: Lucio Cocco, Przemysław Duda, Peter P. Ruvolo, Massimo Libra, Giuseppe Montalto, Agnieszka Gizak, Stefano Ratti, Melchiorre Cervello, Shaw M. Akula, Linda S. Steelman, Dariusz Rakus, Stephen L. Abrams, Alberto M. Martelli, Akshaya K. Meher, Saverio Candido, James A. McCubrey, Luca Falzone

Publikováno v: Cells 10 (2021). doi:10.3390/cells10040816
info:cnr-pdr/source/autori:Stephen L Abrams; Shaw M Akula; Akshaya K Meher; Linda S Steelman; Agnieszka Gizak; Przemys?aw Duda; Dariusz Rakus; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Giuseppe Montalto; Melchiorre Cervello; Peter Ruvolo; Massimo Libra; Luca Falzone; Saverio Candido; James A McCubrey/titolo:GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals/doi:10.3390%2Fcells10040816/rivista:Cells/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:10
Cells
Volume 10
Issue 4
Cells, Vol 10, Iss 816, p 816 (2021)

Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link betwee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9bc9ebd9624ff356255eb057b042a79
http://www.scopus.com/record/display.url?eid=2-s2.0-85105067732&origin=inward